Status: Recruiting
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Muhammad FurqanUpdated: Jun 8, 2026Locations: 5
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+24]
Prior systemic therapy for extensive stage or recurrent SCLC [+28]